CDC Shingles Vaccine and APhA Communication Resources for Pharmacists

Message from CDC

In October 2017, a new shingles vaccine called Shingrix (recombinant zoster vaccine) was recommended by the Advisory Committee on Immunization Practices (ACIP) as preferred over Zostavax (zoster vaccine live), a shingles vaccine in use since 2006. Adults 50 years and older should get two doses of Shingrix, 2 to 6 months apart. The new vaccine is more than 90% effective at preventing shingles and postherpetic neuralgia (PHN). 

The National Center for Immunization and Respiratory Diseases at CDC has developed communication products and resources regarding the new shingles vaccine recommendations. In addition, APhA has developed additional guidance material.

For providers:

For patients: